Analysts See $-0.65 EPS for Sonoma Pharmaceuticals, Inc. (SNOA) as of June, 4

May 17, 2018 - By Patrick Harkless

Investors wait Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA)’s quarterly earnings on June, 4., as reported by RTT. The EPS diference is $0.04 or 5.80 % up from last years number. Previous year: $-0.69; Analysts forcast: $-0.65. Analysts at Wall Street see Sonoma Pharmaceuticals, Inc.’s -10.96 % EPS growth compared to $-0.73 EPS for last quarter. SNOA reached $3.78 during the last trading session after $0.04 change.Sonoma Pharmaceuticals, Inc. has volume of 11,989 shares. Since May 17, 2017 SNOA has declined 45.71% and is downtrending. The stock underperformed the S&P 500 by 57.26%.

Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States, Latin America, Europe, and internationally.The company has $17.93 million market cap. The firm offers Microcyn line of products that are based on electrically charged oxychlorine small molecules designed to target a range of pathogens, such as viruses, fungi, and spores, as well as bacteria, including antibiotic-resistant strains.Last it reported negative earnings. The Company’s products also include Celacyn, a prescription hypochlorous acid based scar management gel; Ceramax Skin Barrier Cream to manage dry itchy skin, minor skin irritations, rashes, and inflammation; Mondoxyne, a prescription oral tetracycline antibiotic for the treatment of various bacterial infections; Alevicyn, a prescription hypochlorous acid based atopic dermatitis product line to reduce itch and pain associated with various dermatoses; and SebuDerm, a prescription topical gel for the management of burning, itching, and scaling in seborrhea and seborrheic dermatitis.

More recent Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) news were brought out by Globenewswire.com, Globenewswire.com and Streetinsider.com. The first one has “Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer” as a title and was brought out on May 08, 2018. The next is “Sonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products” on April 17, 2018. And last was brought out on May 08, 2018, called “Sonoma Pharmaceuticals (SNOA) Appoints Marc Umscheid COO”.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.